Adaptimmune commences synovial sarcoma trial
The company expects to recruit around 10 patients in the trial with an aim to establish the response rate to the therapy. The trial is intended to evaluate
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.